Antifungal stewardship in <scp>Australian</scp> hospitals: defining the scope and future targets
AFS strategies utilised in Australian hospitals have focused on high-cost, intravenous agents. Although expert oversight of antifungals is evident, many sites omit potentially important targets for AFS, including fluconazole and oral posaconazole. Identifying these gaps and barriers to AFS will guide the development of an AFS model for hospitals.
Authors
- Paul D. R. Johnson (ORCID: https://orcid.org/0000-0001-9873-7163)
- Monica A. Slavin (ORCID: https://orcid.org/0000-0002-8443-314X)
- Karen Urbancic (ORCID: https://orcid.org/0000-0002-9275-578X)
- David C. M. Kong (ORCID: https://orcid.org/0000-0002-5022-9060)
- Karin Thursky (ORCID: https://orcid.org/0000-0002-7400-232X)
- Michelle K. Yong (ORCID: https://orcid.org/0000-0002-8692-4145)
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Peter Doherty Institute (AU)
- Austin Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/imj.16571
- Citations
- 2
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.78
Funders
- National Health and Medical Research Council